Johnson & Johnson Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Johnson & Johnson heeft een totaal eigen vermogen van $70.2B en een totale schuld van $35.8B, wat de schuld-eigenvermogensverhouding op 51% brengt. De totale activa en totale passiva bedragen respectievelijk $178.3B en $108.1B. De EBIT Johnson & Johnson is $23.1B waardoor de rentedekking -35.9 is. Het heeft contanten en kortetermijnbeleggingen van $20.3B.

Belangrijke informatie

51.0%

Verhouding schuld/eigen vermogen

US$35.75b

Schuld

Rente dekkingsratio	-35.9x
Contant	US$20.30b
Aandelen	US$70.16b
Totaal verplichtingen	US$108.13b
Totaal activa	US$178.29b

Recente financiële gezondheidsupdates

We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt

Aug 23

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $53.2B ) JNJ } overtreffen de korte termijn passiva ( $51.8B ).

Langlopende schulden: De kortetermijnactiva van JNJ ( $53.2B ) dekken de langetermijnschulden ( $56.4B ) niet.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 22% ) JNJ wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van JNJ is de afgelopen 5 jaar gestegen van 50.2% naar 51%.

Schuldendekking: De schuld van JNJ wordt goed gedekt door de operationele kasstroom ( 70.3% ).

Rentedekking: JNJ verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

Johnson & Johnson Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt

Recent updates

Johnson & Johnson Announces Results from Additional Analyses of the Phase 2 DAHLIA Study Highlighting Improvement in Key Measures of Disease Activity and IgG Reduction

Johnson & Johnson: Tracking Well Above The Industry

Johnson & Johnson Announces U.S. Food and Drug Administration Grants Nipocalimab Breakthrough Therapy Designation for the Treatment of Adults Living with Moderate-To-Severe Sjogren's Disease

Johnson & Johnson Submits Applications in the U.S. and EU Seek Approval of DARZALEX FASPRO® as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma

Johnson & Johnson Announces Results from Phase 3 GRAVITI Study of Tremfya

Johnson & Johnson Highlights Innovative Neuropsychiatry Portfolio and Pipeline at Psych Congress

Johnson & Johnson Announces New Spectrem Study Findings Reveal Tremfya (Guselkumab) Effectively Clears Overlooked and Undertreated Plaque Psoriasis

Johnson & Johnson: Q3 Earnings Highlights Resilience And New Growth

Third quarter dividend of US$1.24 announced

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Johnson & Johnson Announces Positive Results from the Phase 2/3 Vibrance-MG Study of Nipocalimab

Johnson & Johnson Q3 Earnings Preview: Dividend Dependability And Steady Growth

Johnson & Johnson Announces Tremfya Data in Both Crohn's Disease and Ulcerative Colitis

Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide)

Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned

Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens

Johnson & Johnson: A Sell-Rated Dividend King

Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab

Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw)

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Why Investors Shouldn't Be Surprised By Johnson & Johnson's (NYSE:JNJ) P/E

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Johnson & Johnson Announces Executive Changes

We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt

Johnson & Johnson: Don't Bet Against Double Compounding

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib)

Upcoming dividend of US$1.24 per share

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven